RPTX insider filings

Repare Therapeutics Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-01-30. Screen RPTX transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for RPTX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Repare Therapeutics Inc.

FiledFormInsiderReported transactionsSource
2026-01-304BVF PARTNERS L P/IL — 10% owner
BIOTECHNOLOGY VALUE FUND L P — 10% owner
BVF I GP LLC — 10% owner
BIOTECHNOLOGY VALUE FUND II LP
BVF II GP LLC
Biotechnology Value Trading Fund OS LP
BVF Partners OS Ltd.
BVF GP HOLDINGS LLC — 10% owner
BVF INC/IL — 10% owner
LAMPERT MARK N — 10% owner
Code (U): 5,309,432 · Code (U): 4,308,573 · Code (U): 548,938EDGAR
2026-01-284Alves Sandra Isabelle Barros — SVP, Finance and CAODisposition to issuer (D): 31,622 · Disposition to issuer (D): 26,000 (derivative) @ $0 · Disposition to issuer (D): 24,500 (derivative) @ $0EDGAR
2026-01-284Forte Steve — EVP, CHIEF FINANCIAL OFFICERDisposition to issuer (D): 56,786 · Disposition to issuer (D): 200,000 (derivative) @ $0 · Disposition to issuer (D): 85,000 (derivative) @ $0 · Disposition to issuer (D): 500,000 (derivative) @ $0 · Disposition to issuer (D): 325,800 (derivative) @ $0EDGAR
2026-01-284Civik Thomas — DirectorDisposition to issuer (D): 7,500EDGAR
2026-01-284SCHAFER CAROL — DirectorDisposition to issuer (D): 8,000 · Disposition to issuer (D): 37,941 (derivative) @ $0EDGAR
2026-01-284RHOADS ANN D — DirectorDisposition to issuer (D): 4,000EDGAR
2025-04-294Alves Sandra Isabelle Barros — SVP, Finance and CAOGrant/award (A): 4,100 @ $0 · Grant/award (A): 24,500 (derivative) @ $0EDGAR
2025-04-044Forte Steve — EVP, CHIEF FINANCIAL OFFICERGrant/award (A): 500,000 (derivative) @ $0EDGAR
2025-03-144Koehler Maria — EVP, CHIEF MEDICAL OFFICERSale (S): 3,596 @ $1.14EDGAR
2025-03-144Zinda Michael — EVP, CHIEF SCIENTIFIC OFFICERSale (S): 5,611 @ $1.14EDGAR
2025-03-144Forte Steve — EVP, CHIEF FINANCIAL OFFICERSale (S): 6,884 @ $1.14EDGAR
2025-03-144Segal Lloyd Mitchell — PRESIDENT AND CEO, DirectorSale (S): 21,179 @ $1.14EDGAR
2025-03-064Zinda Michael — EVP, CHIEF SCIENTIFIC OFFICERGrant/award (A): 14,000 @ $0 · Grant/award (A): 75,000 (derivative) @ $0 · Grant/award (A): 85,000 (derivative) @ $0EDGAR
2025-03-064Forte Steve — EVP, CHIEF FINANCIAL OFFICERGrant/award (A): 14,000 @ $0 · Grant/award (A): 200,000 (derivative) @ $0 · Grant/award (A): 85,000 (derivative) @ $0EDGAR
2025-03-064Segal Lloyd Mitchell — PRESIDENT AND CEO, DirectorGrant/award (A): 40,000 @ $0 · Grant/award (A): 237,000 (derivative) @ $0EDGAR
2024-06-204Civik Thomas — DirectorGrant/award (A): 27,200 (derivative) @ $0EDGAR
2024-06-204Kulkarni Samarth — DirectorGrant/award (A): 27,200 (derivative) @ $0EDGAR
2024-06-204Stein Steven H — DirectorGrant/award (A): 54,000 (derivative) @ $0EDGAR
2024-06-204Morrison Briggs — DirectorGrant/award (A): 27,200 (derivative) @ $0EDGAR
2024-06-204Bonita David P — DirectorGrant/award (A): 27,200 (derivative) @ $0EDGAR
2024-06-204Molineaux Susan — DirectorGrant/award (A): 27,200 (derivative) @ $0EDGAR
2024-06-204SCHAFER CAROL — DirectorGrant/award (A): 27,200 (derivative) @ $0EDGAR
2024-06-204RHOADS ANN D — DirectorGrant/award (A): 27,200 (derivative) @ $0EDGAR
2024-04-014Forte Steve — EVP, CHIEF FINANCIAL OFFICERSale (S): 825 @ $4.62 · Sale (S): 789 @ $4.61EDGAR
2024-04-014Zinda Michael — EVP, CHIEF SCIENTIFIC OFFICERSale (S): 450 @ $4.64 · Sale (S): 410 @ $4.66EDGAR
2024-04-014Koehler Maria — EVP, CHIEF MEDICAL OFFICERSale (S): 500 @ $4.64 · Sale (S): 300 @ $4.66EDGAR
2024-04-014Segal Lloyd Mitchell — PRESIDENT AND CEO, DirectorSale (S): 2,650 @ $4.62 · Sale (S): 2,491 @ $4.63EDGAR
2024-03-274Forte Steve — EVP, CHIEF FINANCIAL OFFICERSale (S): 825 @ $4.79 · Sale (S): 825 @ $4.60 · Sale (S): 825 @ $4.62EDGAR
2024-03-274Zinda Michael — EVP, CHIEF SCIENTIFIC OFFICERSale (S): 450 @ $4.78 · Sale (S): 450 @ $4.61 · Sale (S): 450 @ $4.62EDGAR
2024-03-274Koehler Maria — EVP, CHIEF MEDICAL OFFICERSale (S): 500 @ $4.78 · Sale (S): 500 @ $4.60 · Sale (S): 500 @ $4.62EDGAR
2024-03-274Segal Lloyd Mitchell — PRESIDENT AND CEO, DirectorSale (S): 2,650 @ $4.79 · Sale (S): 2,650 @ $4.64 · Sale (S): 2,650 @ $4.63EDGAR
2024-03-054Forte Steve — EVP, CHIEF FINANCIAL OFFICERGrant/award (A): 14,000 @ $0 · Grant/award (A): 85,000 (derivative) @ $0EDGAR
2024-03-044Zinda Michael — EVP, CHIEF SCIENTIFIC OFFICERGrant/award (A): 14,000 @ $0 · Grant/award (A): 85,000 (derivative) @ $0EDGAR
2024-03-044Koehler Maria — EVP, CHIEF MEDICAL OFFICERGrant/award (A): 14,000 @ $0 · Grant/award (A): 85,000 (derivative) @ $0EDGAR
2024-03-044Segal Lloyd Mitchell — PRESIDENT AND CEO, DirectorGrant/award (A): 40,000 @ $0 · Grant/award (A): 237,000 (derivative) @ $0EDGAR
2023-12-124Koehler Maria — EVP, Chief Medical OfficerOption exercise (M): 20,190 @ $2.06 · Option exercise (M): 23,556 @ $2.42 · Option exercise (M): 20,190 (derivative) @ $0 · Option exercise (M): 23,556 (derivative) @ $0EDGAR
2023-11-174BVF PARTNERS L P/IL — 10% owner
BIOTECHNOLOGY VALUE FUND L P — 10% owner
BVF I GP LLC — 10% owner
BIOTECHNOLOGY VALUE FUND II LP — 10% owner
BVF II GP LLC — 10% owner
Biotechnology Value Trading Fund OS LP
BVF Partners OS Ltd.
BVF GP HOLDINGS LLC — 10% owner
BVF INC/IL — 10% owner
LAMPERT MARK N — 10% owner
Purchase (P): 493,337 @ $5.00 · Purchase (P): 390,507 @ $5.00 · Purchase (P): 47,712 @ $5.00 · Purchase (P): 153,693 @ $5.38 · Purchase (P): 125,909 @ $5.38 · Purchase (P): 16,143 @ $5.38EDGAR
2023-11-034BVF PARTNERS L P/IL — 10% owner
BIOTECHNOLOGY VALUE FUND L P — 10% owner
BVF I GP LLC — 10% owner
BIOTECHNOLOGY VALUE FUND II LP
BVF II GP LLC
Biotechnology Value Trading Fund OS LP
BVF Partners OS Ltd.
BVF GP HOLDINGS LLC — 10% owner
BVF INC/IL — 10% owner
LAMPERT MARK N — 10% owner
Purchase (P): 218,979 @ $3.60 · Purchase (P): 492,251 @ $3.60 · Purchase (P): 72,479 @ $3.60EDGAR
2023-06-124Civik Thomas — DirectorGrant/award (A): 27,200 (derivative) @ $0EDGAR
2023-06-124Kulkarni Samarth — DirectorGrant/award (A): 27,200 (derivative) @ $0EDGAR
2023-06-124Morrison Briggs — DirectorGrant/award (A): 27,200 (derivative) @ $0EDGAR
2023-06-124Bonita David P — DirectorGrant/award (A): 27,200 (derivative) @ $0EDGAR
2023-06-124Molineaux Susan — DirectorGrant/award (A): 76,200 (derivative) @ $0EDGAR
2023-06-124Foley Todd — DirectorGrant/award (A): 27,200 (derivative) @ $0EDGAR
2023-06-124SCHAFER CAROL — DirectorGrant/award (A): 27,200 (derivative) @ $0EDGAR
2023-06-124RHOADS ANN D — DirectorGrant/award (A): 27,200 (derivative) @ $0EDGAR
2023-06-094Zinda Michael — EVP, Chief Scientific OfficerSale (S): 6,404 @ $12.03 · Sale (S): 2,869 @ $12.02EDGAR
2023-06-074Zinda Michael — EVP, Chief Scientific OfficerSale (S): 1,200 @ $12.04EDGAR
2023-02-014Forte Steve — EVP, Chief Financial OfficerGrant/award (A): 24,530 @ $0 · Grant/award (A): 111,050 (derivative) @ $0EDGAR
2023-02-014Segal Lloyd Mitchell — President and CEO, DirectorGrant/award (A): 78,550 @ $0 · Grant/award (A): 344,200 (derivative) @ $0EDGAR

Recent 8-K events — Repare Therapeutics Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-01-288-K2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-01-168-K5.07 — Submission of Matters to a Vote of Security Holders
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2025-12-298-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2025-12-198-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2025-11-178-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2025-11-148-K2.02 — Results of Operations and Financial Condition
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2025-10-228-K7.01 — Regulation FD DisclosureEDGAR
2025-08-088-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2025-07-168-K1.01 — Entry into a Material Definitive Agreement
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2025-06-208-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=RPTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs